Skip to main content

Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 1-25 of 126

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy with or without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Status: Active
Location: 441 locations
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) after Surgery to Remove all Known Sites of Kidney Cancer
Status: Active
Location: 370 locations
Testing the Addition of Stereotactic Radiation Therapy with Immune Therapy for the Treatment of Patients with Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Status: Active
Location: 273 locations
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients with Cancer That Has Spread to the Brain
Status: Active
Location: 230 locations
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Location: 476 locations
Testing Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Kidney Cancer, PAPMET2 Trial
Status: Active
Location: 166 locations
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Status: Active
Location: 45 locations
STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors
Status: Active
Location: 19 locations
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Status: Active
Location: 17 locations
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Status: Active
Location: 14 locations
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Status: Active
Location: 17 locations
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Status: Active
Location: 14 locations
Stereotactic Body Radiation Therapy for the Treatment of Metastatic Renal Cell Carcinoma in Patients with Oligoprogression on Immune Checkpoint Inhibitors
Status: Active
Location: 12 locations
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Status: Active
Location: 16 locations
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Status: Active
Location: 11 locations
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Status: Active
Location: 11 locations
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Status: Active
Location: 11 locations
Abemaciclib and Cabozantinib for the Treatment of Stage IV Clear Cell or Translocation-Associated Renal Cell Carcinoma in Patients Refractory to Immune Checkpoint Blockade Treatment
Status: Active
Location: 8 locations
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Status: Active
Location: 11 locations
Cemiplimab and Fianlimab before Surgery for the Treatment of Patients with Locally Advanced Kidney Cancer Undergoing Nephrectomy
Status: Active
Location: 7 locations
A Study of Nivolumab in Combination with 177Lu-girentuximab for Kidney Cancer, STARTLITE 2 Study
Status: Active
Location: 7 locations
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
Status: Active
Location: 8 locations
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Status: Active
Location: 7 locations
Study of PYX-201 in Solid Tumors
Status: Active
Location: 7 locations
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Status: Active
Location: 7 locations